The Surat-based specialty chemicals and contract development and manufacturing company is edging toward a full pharmaceutical value chain. On 28 September 2026, Anupam Rasayan India Limited completed a key share purchase and took charge of a listed maker of finished drugs. The step follows a solid first quarter, a recent US acquisition and a steady run of new product launches. Whether integration, funding and returns hold up over the coming quarters is the harder question, and one investors will watch.
Shares of Anupam Rasayan India Ltd are trading at Rs. 1,185.70, down 0.12 percent on Tuesday. The stock touched the intraday high of Rs. 1,196.50 after opening at Rs. 1,187.20 before slipping to a low of Rs. 1,176.10. The company commands a market capitalization of Rs. 13,515.11 crore.
Anupam Rasayan Takes Charge of Bliss GVS Pharma
Anupam Rasayan India Limited has crossed the halfway mark in Bliss GVS Pharma Limited and now runs the company. On 28 September 2026, the Surat-based chemicals maker completed the share purchase agreement it signed in May and received 5,09,84,595 Bliss shares, which is 47.95 percent of the equity. It then bought a further 22,50,000 shares on the market at Rs 723.28 each, a block worth roughly Rs 162.74 crore in cash. With the stake held by its partner Mates Visa Consultancy Private Limited, the pair owns 5,32,36,264 shares, or 50.07 percent. The earlier open offer drew little response, with only 1,669 shares tendered. Bliss’s board met the same day, took note of the change in control and named both parties as promoters.
What the Bliss Deal Changes for Anupam Rasayan
Until now, Anupam Rasayan has sold its chemicals to drug makers rather than to patients. Bliss changes that. The Maharashtra-based company makes suppositories, pessaries, tablets and capsules, sells over 150 brands and operates six plants. Its filing says it has customers in more than 60 countries, with Sub-Saharan Africa the biggest market.
Anupam says it can now connect its key starting materials and intermediates to finished dosage forms, and it wants to use the Vevoor facility to enter regulated CDMO work. The investor presentation puts Bliss’s FY26 revenue at Rs 927 crore. Anupam’s own consolidated revenue that year was Rs 2,384 crore, so consolidating Bliss could alter the size of the group considerably.
The primary challenges lie in funding the initiative and ensuring its operational execution. The full transaction is valued at about Rs 1,600 crore, made up of roughly Rs 1,300 crore through a non-voting equity instrument and around Rs 300 crore of term loan. The debt is small next to the total, yet Anupam already has a heavier interest bill. Finance costs climbed to Rs 49.19 crore in Q1 FY27 from Rs 35.67 crore a year earlier. The Jayhawk acquisition has pushed up employee expenses and depreciation as well, and the consolidated profit margin fell from 10 percent to 8 percent. Taking on two big acquisitions within months will stretch management. The next few results will show whether Bliss adds to profit or only to the balance sheet.
Financial Performance
Looking at the quarterly results of Anupam Rasayan India Limited, the company’s consolidated revenue from operations increased by 34.8 percent YoY, from Rs. 485.83 crore in Q1 FY26 to Rs. 654.98 crore in Q1 FY27, and grew by 3.0 percent QoQ from Rs. 635.78 crore in Q4 FY26.
Anupam Rasayan India Limited generated 41 percent of its consolidated revenue from life science specialty chemicals, 31 percent from performance materials and 28 percent from Tanfac’s fluorinated products, according to its investor presentation. International business made up 36 percent of revenue in Q1 FY27.
In Q1 FY27, Anupam Rasayan India Limited’s consolidated net profit increased by 5.7 percent YOY, reaching Rs. 51.22 crore compared to Rs. 48.46 crore during the same period last year. As compared to Q4 FY26, the net profit has decreased by 8.5 percent, from Rs. 56.00 crore.
The basic earnings per share increased by 9.4 percent and stood at Rs. 3.39 as against Rs. 3.10 recorded in the same quarter in the previous year, FY2026.
Why Indian Drug and Chemical Makers Are Winning More Work
Large drug companies no longer want to rely on a single country for their raw materials, and Indian manufacturers have gained contract work from that change. Anupam Rasayan fits the trend well. It already supplies starting materials and intermediates, and Bliss now lets it sell finished medicines too. Spending on medicines usually holds up when the economy slows, since populations are ageing and chronic illness keeps growing.
Bliss also depends on Sub-Saharan Africa, where anti-malarial products remain in steady demand. There are risks, though. Currency swings, dearer borrowing, tougher drug regulation in the US and Europe, and unpredictable input prices could all squeeze margins, and weaker African currencies may reduce export earnings.
Company Overview
Anupam Rasayan India Limited is a Surat-headquartered specialty chemicals company that earns its living from custom synthesis and contract manufacturing. Customers sit in agrochemicals, pharmaceuticals, personal care and performance materials. Eight plants in India and the United States, some owned by subsidiaries Tanfac and Jayhawk, produce its range. Consolidated revenue for FY26 was Rs 2,384 crore from more than 200 clients.